Difference between revisions of "Editing test page"
m |
m |
||
Line 10: | Line 10: | ||
|- | |- | ||
|colspan="2" style="background-color:#66FF66"|'''[[Tutorial#Regimens|Regimens]]: {{#ask: [[Regimen::+]] |?Regimen |limit=10000|format=sum}}''' | |colspan="2" style="background-color:#66FF66"|'''[[Tutorial#Regimens|Regimens]]: {{#ask: [[Regimen::+]] |?Regimen |limit=10000|format=sum}}''' | ||
− | |colspan="2" style="background-color:#66CCFF"|'''Regimen variants: {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}''' | + | |colspan="2" style="background-color:#66CCFF"|'''[[Tutorial#Variant|Regimen variants]]: {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}''' |
|- | |- | ||
|colspan="4" style="background-color:#505050"| | |colspan="4" style="background-color:#505050"| | ||
|- | |- | ||
− | |style="background-color:# | + | |style="color:white;background-color:#3182bd"|[[#solidtumors|Solid Tumors]] |
− | |style="background-color:# | + | |style="color:white;background-color:#de2d26"|[[#malignantheme|Malignant Heme]] |
− | |style="background-color:# | + | |style="color:white;background-color:#31a354"|[[#otherheme|Other Heme]] |
− | |style="background-color:# | + | |style="color:white;background-color:#756bb1"|[[#transplant|Transplant]] |
|- | |- | ||
|colspan="4" background-color:#FFFFE0"|<big>[[Editorial Board]]</big> | |colspan="4" background-color:#FFFFE0"|<big>[[Editorial Board]]</big> | ||
Line 26: | Line 26: | ||
|style="background-color:#F0F0F0"|[[:Category:General reference pages|General reference]] | |style="background-color:#F0F0F0"|[[:Category:General reference pages|General reference]] | ||
|- | |- | ||
− | |[[ | + | |'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_desktop Desktop Version]''' |
− | |[[ | + | |'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile Mobile Version]''' |
− | |[[ | + | |'''[[How to add HemOnc.org to your home screen | Mobile shortcut]]''' |
+ | |'''[[Hematology Oncology Fellowship Programs Directory|Fellowship programs]]''' | ||
|} | |} | ||
Line 36: | Line 37: | ||
<span id="solidtumors"></span> | <span id="solidtumors"></span> | ||
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | {| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
− | !colspan="4" align="center" style="color:white; font-size:150%; background-color:# | + | !colspan="4" align="center" style="color:white; font-size:150%; background-color:#3182bd"| '''Solid Tumors''' |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Breast Oncology''' |
|- | |- | ||
− | |colspan="2" style="background-color:# | + | |colspan="2" style="background-color:#deebf7"|[[Breast cancer]] |
− | |colspan="2" style="background-color:# | + | |colspan="2" style="background-color:#deebf7"|[[Breast cancer, HER-2 positive]] |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Dermatologic Oncology''' |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Melanoma]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Basal cell and squamous cell skin cancer | Skin, basal & squamous cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Merkel cell carcinoma]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Endocrine Oncology''' |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Germ cell tumors]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Neuroendocrine tumors]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Thyroid cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Gastrointestinal Oncology''' |
|- | |- | ||
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#deebf7"|[[Anal cancer]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#deebf7"|[[Colon cancer]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#deebf7"|[[Gastric cancer]] |
|- | |- | ||
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#deebf7"|[[Hepatobiliary cancer]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#deebf7"|[[Rectal cancer]] |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Genitourinary Oncology''' |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Bladder cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Germ cell tumors]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Penile cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Prostate cancer]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Renal cancer|Renal cancer (RCC)]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Testicular cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Gynecologic Oncology''' |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Cervical cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Germ cell tumors]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Ovarian cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Uterine cancer]] |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Head & Neck Oncology''' |
|- | |- | ||
− | |colspan="2" style="background-color:# | + | |colspan="2" style="background-color:#deebf7"|[[Head and neck cancer]] |
− | |colspan="2" style="background-color:# | + | |colspan="2" style="background-color:#deebf7"|[[Thyroid cancer]] |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Neuro-Oncology''' |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Central nervous system (CNS) cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Glioblastoma]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[CNS leukemia]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[CNS lymphoma]] |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Pediatric Oncology''' |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#deebf7"|[[Neuroblastoma]] |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Sarcoma''' |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Bone cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Ewing's sarcoma]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Osteosarcoma]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Sarcoma]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Thoracic Oncology''' |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Esophageal cancer]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Non-small cell lung cancer | Lung cancer, non-small cell (NSCLC)]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Small cell lung cancer | Lung cancer, small cell (SCLC)]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Mesothelioma]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Thymoma]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#9ecae1"|'''Site-agnostic''' |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[MSI-H or dMMR]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"|[[Unknown primary]] |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
− | |style="background-color:# | + | |style="background-color:#deebf7"| |
|- | |- | ||
|} | |} | ||
Line 142: | Line 143: | ||
|} | |} | ||
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | {| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
− | !colspan="4" align="center" style="color:white; font-size:150%; background-color:# | + | !colspan="4" align="center" style="color:white; font-size:150%; background-color:#de2d26"| '''Malignant Hematology''' |
|- | |- | ||
− | |colspan="4" style="background-color:# | + | |colspan="4" style="background-color:#fc9272"|'''Acute leukemias''' |
|- | |- | ||
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)]] |
|- | |- | ||
− | | | + | |colspan="4" style="background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes''' |
− | |||
− | |||
− | |||
|- | |- | ||
− | | | + | |style="background-color:#fee0d2"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]] |
+ | |style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]] | ||
+ | |style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]] | ||
+ | |style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]] | ||
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Myelodysplastic syndrome]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Systemic mastocytosis]] |
|- | |- | ||
− | | | + | |colspan="4" style="background-color:#fc9272"|'''Mature B-, T-, and NK-cell neoplasms''' |
− | |||
− | |||
− | |||
|- | |- | ||
− | | | + | |style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]] |
+ | |style="background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]] | ||
+ | |style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]] | ||
+ | |style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | Chronic lymphocytic leukemia (CLL/SLL)]] | ||
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[CNS lymphoma]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Extranodal NK/T-cell lymphoma, nasal type]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[HIV-associated lymphoma]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Hodgkin lymphoma|Hodgkin lymphoma (HL)]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (MM)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[NK/T-cell lymphoma]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Plasma cell leukemia]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]] |
− | |style="background-color:# | + | |style="background-color:#fee0d2"| |
− | |style="background-color:# | + | |style="background-color:#fee0d2"| |
|- | |- | ||
− | |style="background-color:# | + | |} |
− | |style="background-color:# | + | <span id="transplant"></span> |
− | |style="background-color:# | + | {| class="wikitable" style="float:right; margin-left: 5px;" |
− | |style="background-color:# | + | |- |
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | {| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
+ | |colspan="4" align="center" style="color:white; font-size:150%; background-color:#756bb1"|'''Transplant''' | ||
+ | |- | ||
+ | |style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]] | ||
+ | |style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT conditioning regimens]] | ||
+ | |style="width: 25%; background-color:#efedf5"|[[Autologous HSCT conditioning regimens]] | ||
+ | |style="width: 25%; background-color:#efedf5"|[[Graft versus host disease (GVHD)]] | ||
|- | |- | ||
|} | |} | ||
Line 212: | Line 222: | ||
|} | |} | ||
{| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | {| border="1" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;" | ||
− | |colspan="4" align="center" style="color:white; font-size:150%; background-color:# | + | |colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Other Hematology''' |
|- | |- | ||
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#e5f5e0"|[[Aplastic anemia]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#e5f5e0"|[[Atypical hemolytic-uremic syndrome (aHUS)]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#e5f5e0"|[[Autoimmune cytopenias]] |
− | |style="width: 25%; background-color:# | + | |style="width: 25%; background-color:#e5f5e0"|[[Autoimmune thrombocytopenic purpura (ITP)]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#e5f5e0"|[[Castleman disease]] |
− | |style="background-color:# | + | |style="background-color:#e5f5e0"|[[Coagulopathies]] |
− | |style="background-color:# | + | |style="background-color:#e5f5e0"|[[Cold agglutinin disease]] |
− | |style="background-color:# | + | |style="background-color:#e5f5e0"|[[Hemophagocytic lymphohistiocytosis (HLH)]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#e5f5e0"|[[Histiocytoses]] |
− | |style="background-color:# | + | |style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria (PNH)]] |
− | |style="background-color:# | + | |style="background-color:#e5f5e0"|[[Sickle cell anemia]] |
− | |style="background-color:# | + | |style="background-color:#e5f5e0"|[[Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura (TTP)]] |
|- | |- | ||
− | |style="background-color:# | + | |style="background-color:#e5f5e0"|[[Venous thromboembolism (VTE)]] |
− | |style="background-color:# | + | |style="background-color:#e5f5e0"| |
− | |style="background-color:# | + | |style="background-color:#e5f5e0"| |
− | |style="background-color:# | + | |style="background-color:#e5f5e0"| |
|- | |- | ||
|} | |} |
Revision as of 03:06, 4 October 2017
HemOnc.org - A Free Hematology/Oncology Reference
Links to Main Disease Pages
back to top |
back to top |
Transplant | |||
Stem cell mobilization | Allogeneic HSCT conditioning regimens | Autologous HSCT conditioning regimens | Graft versus host disease (GVHD) |
back to top |
Additional Information
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100s of hematology/oncology drugs, and 1000s of antineoplastic regimens. Content is added by hematology & oncology providers, and undergoes continuous peer review.
Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details. Priorities of this project include:
- Creating a database of chemotherapy agents and other medications.
- Creating a database of chemotherapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
- Sample order sets and examples of supportive medications used with treatment regimens
- Aggregating useful links to existing resources by disease, such as information about prognosis, clinical calculators, staging, and patient resources.
Additional possibilities for this project may include:
- Creating summaries of pivotal clinical trials
- Establishing homepages for ongoing clinical trials that contain information and sites of participation
- Checklists for common clinical scenarios/diseases
- Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.